Cipla Ltd has entered into a joint venture agreement with Kemwell Biopharma Private Limited to set up a new company in India focused on biologic medicines. The partnership will operate as a 60:40 venture, with Cipla holding the majority stake.
As per the filing, the proposed company will undertake activities related to the development, licensing, manufacturing and commercialisation of biologic products. It may also handle import and export of such products and can license or outsource parts of the work where required.
The partners plan to invest up to ₹10 crore initially in the joint venture, based on their respective shareholding ratio. The investment will be made in cash.
At the time of incorporation, Cipla will subscribe to 6,000 equity shares with a face value of ₹10 each at par value, amounting to ₹60,000.
The joint venture entity is yet to be incorporated, and therefore financial details such as turnover are not applicable at this stage.
Kemwell Biopharma operates as a biologics contract development and manufacturing organisation serving global pharmaceutical companies. Its facility in Bengaluru follows current Good Manufacturing Practice (cGMP) standards and has been certified by the United States Food and Drug Administration (USFDA).
The site includes a 5,000-litre bioreactor capacity along with sterile fill–finish capabilities. It also houses development laboratories focused on protein therapeutics and supports research, clinical programmes and commercial manufacturing for biologics and biosimilars.
Separately, Cipla (EU) Limited, the company’s wholly owned subsidiary in the United Kingdom, has incorporated another wholly owned subsidiary named Cipla Middle East Company in the Kingdom of Saudi Arabia.
Read More: Pine Labs to Roll Out Stablecoin Backed Prepaid Card says CEO!
As of March 2, 2026, 3:30 pm, Cipla Ltd share price closed at ₹1,351.00, a 0.21% increase from the previous closing price.
The joint venture will focus on developing and manufacturing biologic products for global markets, combining Cipla’s pharmaceutical presence with Kemwell’s biologics manufacturing infrastructure.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Mar 4, 2026, 9:07 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
